Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06681896

Microvascular Coronary Rehabilitation For Improving Treatment – Feasibility Study

Microvascular Coronary Rehabilitation For Improving Treatment – Feasibility Study — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06681896.

📅 14 Aug 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06681896
Sponsor
Royal United Hospitals Bath NHS Foundation Trust
Start
2024-11-12
ClinicaliQ Trial Snapshot
  • Microvascular Coronary Rehabilitation For Improving Treatment – Feasibility Study — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06681896.
  • What is being tested: A personalised cardiac rehabilitation programme called MICROFIT combining high-intensity interval exercise (HIIT) and dietary advice, designed to improve outcomes in patients with microvascular coronary disease.
  • Patient eligibility overview: This feasibility study targets patients with microvascular coronary dysfunction (microvascular angina), a condition characterised by chest pain and ischaemia despite normal coronary arteries on angiography.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to assess the feasibility of undertaking a randomized controlled trial assessing the impact of a personalised, intense cardiac rehabilitation programme involving high intensity interval exercise (HIIT) and dietary advice (termed MICROFIT) on symptom burden in patients with microvascular coronary dysfunction. The main questions it aims to answer are: 1. Feasibility of undertaking randomised controlled trial of MICROFIT in patients with coronary microvascular dysfunction (recruitment rates, retention and adherence, acceptability of MICROFIT and participants' and practitioners' experiences of trial participation) 2. Preliminary data on…

Eligibility Snapshot
  • : * Age ≥18 * Angina or angina equivalent symptoms * Unobstructed coronary arteries at the time of coronary angiogram. This will be defined as plaque causing

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Cardiology / Cardiovascular · 30 Mar 2026
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
The ‘heartbreaking’ OCD that can make you doubt your relationship
Cardiology / Cardiovascular · BBC Health · 16 Jul 2026
Relationship OCD is an underrecognised condition characterised by intrusive doubts about romantic partnerships, requiring greater clinical awareness for timely diagnosis and intervention…
View brief →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →
Guideline
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Cardiology / Cardiovascular · 16 Jul 2026
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or…
View guideline →
Clinical Brief
Man completes half marathon after two heart attacks
Cardiology / Cardiovascular · BBC Health · 26 Aug 2026
Key Takeaways for Clinical Practice Cardiac rehabilitation and secondary prevention can enable significant functional recovery post-myocardial infarction, with patients potentially returning to…
View brief →